Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Shares Issued (2016 - 2025)

Historic Shares Issued for Viking Therapeutics (VKTX) over the last 11 years, with Q3 2025 value amounting to $436000.0.

  • Viking Therapeutics' Shares Issued fell 8265.02% to $436000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 7659.55%. This contributed to the annual value of $10.8 million for FY2024, which is 5976.65% up from last year.
  • Viking Therapeutics' Shares Issued amounted to $436000.0 in Q3 2025, which was down 8265.02% from $551000.0 recorded in Q2 2025.
  • Viking Therapeutics' 5-year Shares Issued high stood at $5.7 million for Q1 2021, and its period low was $5000.0 during Q3 2021.
  • Its 5-year average for Shares Issued is $1.6 million, with a median of $614000.0 in 2022.
  • The largest annual percentage gain for Viking Therapeutics' Shares Issued in the last 5 years was 344000.0% (2021), contrasted with its biggest fall of 9757.28% (2021).
  • Quarter analysis of 5 years shows Viking Therapeutics' Shares Issued stood at $66000.0 in 2021, then soared by 127.27% to $150000.0 in 2022, then increased by 12.0% to $168000.0 in 2023, then skyrocketed by 495.24% to $1.0 million in 2024, then plummeted by 56.4% to $436000.0 in 2025.
  • Its Shares Issued was $436000.0 in Q3 2025, compared to $551000.0 in Q2 2025 and $349000.0 in Q1 2025.